FDA-Approved Biosimilar Insulin: Good Enough for Critical Care, Adulterated, or Counterfeit? How Can We Tell?

If a biosimilar insulin is discovered postmarketing to be subpotent, superpotent, or contaminated or the contents mislabeled, it is an adulterated product and must be quarantined for removal including from a patient’s home. Adulterated products could be considered “counterfeit” since they do not mee...

Full description

Saved in:
Bibliographic Details
Published in:J Diabetes Sci Technol
Main Author: Carter, Alan W.
Format: Artigo
Language:Inglês
Published: SAGE Publications 2014
Subjects:
Letters to the Editor
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4455370/
https://ncbi.nlm.nih.gov/pubmed/25172881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296814539275
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items